Innovative Pharmaceutical Biotech (HKG:0399) entered a memorandum of understanding to invest in US-based Niraxx in exchange for a majority stake, a Tuesday Hong Kong bourse filing said.
Niraxx developed SyncWell, an artificial intelligence-powered virtual health platform, and DeepSynaps, a neurotechnology service platform.
Niraxx is also in the business of integrating photobiomodulation technology into activewear and developing a computer chip that integrates advanced technologies.
The oral insulin products seller said the potential investment is part of the group's business diversification efforts.
The parties have yet to enter a formal agreement, as stated in the disclosure.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.